Chris Howerton
Stock Analyst at Jefferies
(2.52)
# 2,307
Out of 4,944 analysts
74
Total ratings
44.07%
Success rate
14.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.75 | +39.13% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $19.16 | +312.32% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.74 | +129.89% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $3.41 | +193.26% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $5.60 | +6,185.71% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $9.08 | +7,833.88% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.49 | -66.44% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $20.11 | -50.27% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $5.14 | -61.09% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $13.77 | -20.12% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $26.58 | +50.49% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $36.67 | +66.35% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $109.39 | -17.73% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.36 | +175.23% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.27 | +9,821.26% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.31 | +1,426.72% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $24.99 | +164.11% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.40 | +243.75% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.77 | +1,086.44% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.35 | +1,529.63% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.53 | +1,403.27% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $25.13 | -16.43% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $15.97 | +3,531.81% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.14 | +5,163.16% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $72.80 | -78.02% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $56.72 | -52.40% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $7.29 | +16,360.91% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.75
Upside: +39.13%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $19.16
Upside: +312.32%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.74
Upside: +129.89%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $3.41
Upside: +193.26%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $5.60
Upside: +6,185.71%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $9.08
Upside: +7,833.88%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.49
Upside: -66.44%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $20.11
Upside: -50.27%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $5.14
Upside: -61.09%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $13.77
Upside: -20.12%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $26.58
Upside: +50.49%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $36.67
Upside: +66.35%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $109.39
Upside: -17.73%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.36
Upside: +175.23%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.27
Upside: +9,821.26%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.31
Upside: +1,426.72%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $24.99
Upside: +164.11%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $6.40
Upside: +243.75%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.77
Upside: +1,086.44%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.35
Upside: +1,529.63%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.53
Upside: +1,403.27%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $25.13
Upside: -16.43%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $15.97
Upside: +3,531.81%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.14
Upside: +5,163.16%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $72.80
Upside: -78.02%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $56.72
Upside: -52.40%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $7.29
Upside: +16,360.91%